Cargando…
Using a Validated Calculator to Assess the Risk of Disease Progression and Treatment Completion in Patients with Human Immunodeficiency Virus Infection and Latent TB
BACKGROUND: HIV-infection leads to a higher risk of progression from asymptomatic, non-transmissible latent tuberculosis infection (LTBI) to active tuberculosis (TB). Specific comorbid medical risk factors increase this risk which can be decreased by successfully treating LTBI. METHODS: We compared...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631657/ http://dx.doi.org/10.1093/ofid/ofx163.413 |
_version_ | 1783269525900230656 |
---|---|
author | Scolarici, Michael Dekitani, Ken Chatterjee, Soumya |
author_facet | Scolarici, Michael Dekitani, Ken Chatterjee, Soumya |
author_sort | Scolarici, Michael |
collection | PubMed |
description | BACKGROUND: HIV-infection leads to a higher risk of progression from asymptomatic, non-transmissible latent tuberculosis infection (LTBI) to active tuberculosis (TB). Specific comorbid medical risk factors increase this risk which can be decreased by successfully treating LTBI. METHODS: We compared risk of progression between HIV infected and uninfected adults seen at the Saint Louis University hospital from 2010 to 2015 using a validated online calculator (tstin3d.com). We also recorded information on prescribing practices and treatment completion rates in the two groups. RESULTS: Of 125 patients included, 10 had HIV, 10 AIDS, and 105 HIV-uninfected. The median annual TB-risk amongst the three groups was 8% (3–8%), 22% (21–25%), and 0.5% (0–6%) respectively. Smoking, recent TST/IGRA conversion, and diabetes were more prevalent among HIV/AIDS patients. Nine months of INH was most commonly prescribed for both HIV/AIDS (85%) and HIV-uninfected groups (45%). Of concern, were the equivalent rates of LTBI treatment non-completion seen between HIV/AIDS than HIV-uninfected patients (35% vs. 34%). CONCLUSION: TSTin3D.com can facilitate increased provider awareness of TB activation risk factors and can quantitate risk of reactivation. We are currently implementing the calculator in the clinic to prospectively study how risk stratification can alter treatment choices for LTBI patients at highest risk for progression to TB. DISCLOSURES: All authors: No reported disclosures. |
format | Online Article Text |
id | pubmed-5631657 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-56316572017-11-07 Using a Validated Calculator to Assess the Risk of Disease Progression and Treatment Completion in Patients with Human Immunodeficiency Virus Infection and Latent TB Scolarici, Michael Dekitani, Ken Chatterjee, Soumya Open Forum Infect Dis Abstracts BACKGROUND: HIV-infection leads to a higher risk of progression from asymptomatic, non-transmissible latent tuberculosis infection (LTBI) to active tuberculosis (TB). Specific comorbid medical risk factors increase this risk which can be decreased by successfully treating LTBI. METHODS: We compared risk of progression between HIV infected and uninfected adults seen at the Saint Louis University hospital from 2010 to 2015 using a validated online calculator (tstin3d.com). We also recorded information on prescribing practices and treatment completion rates in the two groups. RESULTS: Of 125 patients included, 10 had HIV, 10 AIDS, and 105 HIV-uninfected. The median annual TB-risk amongst the three groups was 8% (3–8%), 22% (21–25%), and 0.5% (0–6%) respectively. Smoking, recent TST/IGRA conversion, and diabetes were more prevalent among HIV/AIDS patients. Nine months of INH was most commonly prescribed for both HIV/AIDS (85%) and HIV-uninfected groups (45%). Of concern, were the equivalent rates of LTBI treatment non-completion seen between HIV/AIDS than HIV-uninfected patients (35% vs. 34%). CONCLUSION: TSTin3D.com can facilitate increased provider awareness of TB activation risk factors and can quantitate risk of reactivation. We are currently implementing the calculator in the clinic to prospectively study how risk stratification can alter treatment choices for LTBI patients at highest risk for progression to TB. DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2017-10-04 /pmc/articles/PMC5631657/ http://dx.doi.org/10.1093/ofid/ofx163.413 Text en © The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Abstracts Scolarici, Michael Dekitani, Ken Chatterjee, Soumya Using a Validated Calculator to Assess the Risk of Disease Progression and Treatment Completion in Patients with Human Immunodeficiency Virus Infection and Latent TB |
title | Using a Validated Calculator to Assess the Risk of Disease Progression and Treatment Completion in Patients with Human Immunodeficiency Virus Infection and Latent TB |
title_full | Using a Validated Calculator to Assess the Risk of Disease Progression and Treatment Completion in Patients with Human Immunodeficiency Virus Infection and Latent TB |
title_fullStr | Using a Validated Calculator to Assess the Risk of Disease Progression and Treatment Completion in Patients with Human Immunodeficiency Virus Infection and Latent TB |
title_full_unstemmed | Using a Validated Calculator to Assess the Risk of Disease Progression and Treatment Completion in Patients with Human Immunodeficiency Virus Infection and Latent TB |
title_short | Using a Validated Calculator to Assess the Risk of Disease Progression and Treatment Completion in Patients with Human Immunodeficiency Virus Infection and Latent TB |
title_sort | using a validated calculator to assess the risk of disease progression and treatment completion in patients with human immunodeficiency virus infection and latent tb |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631657/ http://dx.doi.org/10.1093/ofid/ofx163.413 |
work_keys_str_mv | AT scolaricimichael usingavalidatedcalculatortoassesstheriskofdiseaseprogressionandtreatmentcompletioninpatientswithhumanimmunodeficiencyvirusinfectionandlatenttb AT dekitaniken usingavalidatedcalculatortoassesstheriskofdiseaseprogressionandtreatmentcompletioninpatientswithhumanimmunodeficiencyvirusinfectionandlatenttb AT chatterjeesoumya usingavalidatedcalculatortoassesstheriskofdiseaseprogressionandtreatmentcompletioninpatientswithhumanimmunodeficiencyvirusinfectionandlatenttb |